More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2024 financial results and provided a corporate update.

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Joseph Tucker, Chief Executive Officer and Director of Enveric ...

AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive ...

Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...

Nitric Boost Ultra is a male health support supplement that has been receiving much attention lately. The manufacturer claims ...

ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an "alternative source ...

The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...